Real-world data show that Enhertu benefits those with HR+ breast cancer, whereas Trodelvy is effective as an initial treatment for HER2-null/HER2– disease.

Q2 2025 Earnings Call Transcript August 13, 2025 Mersana Therapeutics, Inc. misses on earnings expectations. Reported EPS is ...

Q2 2025 Earnings Call Transcript August 8, 2025 Operator: Good afternoon, everyone. Thank you for standing by. Welcome to the ...

Even though oncology segment revenue inched up just 1 percent year over year, the firm lifted full-year expectations slightly ...

NEW YORK – ProteinQure said Thursday that the US Food and Drug Administration and Health Canada cleared it to begin a Phase I trial of its lead candidate, the peptide-drug conjugate PQ203, in ...

Shares in Gilead Sciences were a massive 9% higher in Friday’s early trading after the US biotech major lifted its full-year financial guidance.

(Reuters) -Gilead Sciences on Thursday reported flat quarterly earnings on slightly higher revenue and raised its full-year ...

The Foster City, Calif.-based biopharmaceutical company said the growth was driven by Biktarvy, Descovy, Trodelvy and ...

TORONTO, Canada I August 07, 2025 I ProteinQure, a leader in computational protein drug discovery, today announced it has received regulatory clearance from ...

Analysts expect Gilead Sciences to report an earnings per share (EPS) of $1.95. Investors in Gilead Sciences are eagerly ...

Gilead Sciences, Inc. GILD announced positive data on breast cancer drug Trodelvy (sacituzumab govitecan-hziy) from the late-stage ASCENT-04/KEYNOTE-D19 study.

GILD posts strong phase III results for Trodelvy plus Keytruda, cutting TNBC progression risk by 35% compared with standard care.